A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma †
Titel:
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma †
Auteur:
Roy, A.C. Park, S.R. Cunningham, D. Kang, Y.K. Chao, Y. Chen, L.T. Rees, C. Lim, H.Y. Tabernero, J. Ramos, F.J. Kujundzic, M. Cardic, M.B. Yeh, C.G. de Gramont, A.